KDR and glioblastoma: PDGFRA was expressed in 196/341 (57.5%) cases (41/49, 83.7% anaplastic oligodendroglioma; 11/19, 57.9% anaplastic astrocytoma; 144/273, 52.7% glioblastoma); KIT expressed in 56/332 (16.9%) cases (17/44, 38.6% anaplastic oligodendroglioma; 2/16, 12.5% anaplastic astrocytoma; 37/272, 13.6% glioblastoma); and VEGFR2 expressed in 5/341 (1.5%) cases (0/48, 0% anaplastic oligodendroglioma; 0/16, 0% anaplastic astrocytoma; 5/257, 1.9% glioblastoma).